Skip to main content

Table 1 Summary of patients´ treatment

From: Glomerular proteomic profiling reveals early differences between preexisting and de novo type 2 diabetes in human renal allografts

 

PTDM

T2DM

NG

Corticosteroids

7/7 (100%)

6/6 (100%)

4/4 (100%)

Mycophenolate

7/7 (100%)

6/6 (100%)

4/4 (100%)

Tacrolimus

7/7 (100%)

6/6 (100%)

4/4 (100%)

Insulin

0/8 (0%)

6/6 (100%)

0/4 (0%)

Other antidiabetics

3/7 (43%)

1/6 (16,6%)

0/4 (0%)

Antihypertensive drugs

6/7 (86%)

6/6 (100%)

4/4 (100%)